Patents Assigned to Chu Strasbourg, Les Hôpitaux Universitaires de Strasbourg
-
Publication number: 20220411493Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.Type: ApplicationFiled: April 29, 2022Publication date: December 29, 2022Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas BAUMERT, Rajeevkumar Tawar
-
Patent number: 11365251Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).Type: GrantFiled: October 27, 2020Date of Patent: June 21, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Publication number: 20210040204Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).Type: ApplicationFiled: October 27, 2020Publication date: February 11, 2021Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Patent number: 10851160Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.Type: GrantFiled: March 21, 2017Date of Patent: December 1, 2020Assignees: Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg, Chu Strasbourg, les Hopitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Publication number: 20190100586Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.Type: ApplicationFiled: March 21, 2017Publication date: April 4, 2019Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar